Bonraybio is set to go public and list on the Innovation Board in early December, with an initial public offering price tentatively set at NT$108 per share. On the 29th, Cheng-Teng Hsu, Chairman and CEO of Bonraybio, stated that the company has gained international recognition through its comprehensive solutions for male infertility. With products now marketed in 53 countries, Bonraybio is poised to benefit from the rapidly expanding global assisted reproduction industry. Revenue for the first three quarters of this year has already matched the company’s performance for the entire previous year, with an after-tax earnings per share (EPS) of NT$1.56 for the first half of the year, surpassing last year’s full-year EPS of NT$1.51.
Read more
